Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Recombinant chimeric/humanized hybrid (mouse/human) antibody expressed in CHO binding to human CD248. Ontuxizumab is a monoclonal antibody designed for the treatment of cancer.
Target
CD248
Type
IgG1 - kappa
Immunogen
The details of the immunogen for this antibody are not available.
Species Reactivity
Human
Expression Host
CHO
Applications
Suitable for use in Neut, ELISA, IF, IP, FuncS, FC, ICC and most other immunological methods.
CAS
946415-62-9
Predicted N terminal
QVQLQESG
Molecular Weight
147.0 kDa
Purity
>95.0% as determined by analysis by SDS-PAGE.
Size
1mg
Storage
Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°C.
BACKGROUND
Introduction
Ontuxizumab is a monoclonal antibody designed for the treatment of cancer and binds to TEM1.
Antigen Description
Endosialin is a protein that in humans is encoded by the CD248 gene.Endosialin is a member of the "Group XIV", a novel family of C-type lectin transmembrane receptors which play a role not only in cell-cell adhesion processes but also in host defence. This family comprise two other members, CD93 and Thrombomodulin which are better characterized. Even though the function of endosialin remains elusive, its expression has been associated with angiogenesis in the embryo, uterus and in tumor development and growth.
Function
binding; calcium ion binding; molecular_function; sugar binding;